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The 5′ end of the breast and ovarian cancer–susceptibility gene BRCA1 has previously been shown to lie within a
duplicated region of chromosome band 17q21. The duplicated region contains BRCA1 exons 1A, 1B, and 2 and
their surrounding introns; as a result, a BRCA1 pseudogene (WBRCA1) lies upstream of BRCA1. However, the
sequence of this segment remained essentially unknown. We needed this information to investigate at the nucleotide
level the germline deletions comprising BRCA1 exons 1A, 1B, and 2, which we had previously identified in two
families with breast and ovarian cancer. We have analyzed the recently deposited nucleotide sequence of the 1.0-
Mb region upstream of BRCA1. We found that 14 blocks of homology between the tandemly repeated copies
(cumulative lengthp 11.5 kb) show similarity of 77%–92%. Gaps between blocks result from insertion or deletion,
usually of repetitive elements. BRCA1 exon 1A and WBRCA1 exon 1A are 44.5 kb apart. In the two families with
breast and ovarian cancer mentioned above, distinct homologous recombination events occurred between intron
2 of BRCA1 and intron 2 of WBRCA1, leading to 37-kb deletions. Breakpoint junctions were found to be located
at close but distinct sites within segments that are 98% identical. The mutant alleles lack the BRCA1 promoter
and harbor a chimeric gene consisting of WBRCA1 exons 1A, 1B, and 2, which lacks the initiation codon, fused
to BRCA1 exons 3–24. Thus, we report a new mutational mechanism for the BRCA1 gene. The presence of a
large region homologous to BRCA1 on the same chromosome appears to constitute a hot spot for recombination.
Introduction
More and more germline rearrangements have been iden-
tified in the BRCA1 gene (MIM 113705) during the last
4 years, in families with breast and/or ovarian cancer
(Petrij-Bosch et al. 1997; Puget et al. 1997; Swensen et
al. 1997; Montagna et al. 1999; Puget et al. 1999a,
1999b; Payne et al. 2000; Rohlfs et al. 2000a, 2000b;
Unger et al. 2000; Gad et al. 2001a, 2001b). This is due
to the fact that a growing number of laboratories screen-
ing for mutations in BRCA1 use techniques allowing their
identification—that is, Southern blot analysis (Swensen et
al. 1997;Montagna et al. 1999; Puget et al. 1999a;Rohlfs
et al. 2000b; Unger et al. 2000; Lahti-Domenici et al.
2001), cDNA analysis (Petrij-Bosch et al. 1997; Puget et
al. 1997, 1999b; Rohlfs et al. 2000a), DNA combing
(Gad et al. 2001a, 2001b), long-range PCR (Payne et al.
2000), and semiquantitative PCR (Robinson et al. 2000).
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Indeed, 20 different large alterations have been re-
ported, among which 14 are fully characterized. All
these rearrangements share several characteristics with
the far more numerous point mutations found in
BRCA1: they are scattered throughout the gene, 160%
are unique, and the recurrence of certain mutations is
due to founder effects (Petrij-Bosch et al. 1997; The
BRCA1 Exon 13 Duplication Screening Group 2000;
Rohlfs et al. 2000b). The breakpoint junction of only
one rearrangement falls within an exonic sequence
(Payne et al. 2000). In all other cases, they fall within
intronic Alu sequences, which represent 41.5% of the
BRCA1 gene (Smith et al. 1996).
In a previous study (Puget et al. 1999a), we identified
two different germline deletions that involve exons 1
and 2 and whose breakpoints could not be characterized
because knowledge of the structure of the region up-
stream of BRCA1 was not comprehensive. A BRCA1
pseudogene, WBRCA1, had been shown to lie ∼30 kb
upstream of BRCA1 (Barker et al. 1996; Brown et al.
1996), because of the duplication of a region containing
BRCA1 exons 1 and 2. The first exons of the NBR2
(next to BRCA1 2) gene, located between BRCA1 and
its pseudogene, are homologous to the first exons of the
NBR1 (next to BRCA1 1) gene, which lies head-to-head
with WBRCA1 (Xu et al. 1997). The deletions we iden-
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tified in the two families with breast and ovarian can-
cer, F32 and F3514, did not include WBRCA1 exons
1 and 2 (Puget et al. 1999a) but were found to totally
encompass NBR2 (data not shown). We suspected that
the existence of the duplicated regions could represent
a recombination hot spot and could be involved in pre-
disposition to breast and ovarian cancer in families F32
and F3514.
On the basis of a color bar code of the BRCA1 region
on combed DNA in carriers, we show evidence in favor
of this hypothesis. The recent availability of the full
sequence of the 1-Mb region upstream of BRCA1 al-
lowed us (1) to describe its precise organization, which
revealed its high potential of recombination and (2) to
use PCR to characterize the deletions’ breakpoints. This
showed that both recombinations occurred between in-
tron 2 of the pseudogene and intron 2 of the gene, at
close, but not identical, sites. These findings strengthen
the hypothesis that the presence of a large region ho-
mologous to BRCA1 and on the same chromosomemay
constitute a hot spot for recombination.
Subjects and Methods
Sequence Data Analyses
The sequence of BAC RP11-242D8 (GenBank ac-
cession number AC060780) was identified by per-
forming a BLAST search with BRCA1 intron 2, using
a “human repeats” filter in the High-Throughput Ge-
nome Sequences database. The sequence was, at the time
this manuscript was written, a “working draft” con-
sisting of three contigs and not yet annotated. Because
the first 39 kb of the first contig (152,199 bp) is the only
one to contain BRCA1 sequences (from exon 1A tomost
of intron 12), it is certain to be a clone end. Therefore,
coordinates given in the present report will not change
when the sequence is updated. Exons of NBR1 and
NBR2 were positioned within the sequence by use of
the SIM4 program, while “exons” 1A, 1B, and 2 of
WBRCA1 were defined by means of homology with
BRCA1 exons, using the BLAST program. The extent
of the similarity between gene and pseudogene was in-
vestigated using the LALIGN program. Blocks were ar-
bitrarily defined as regions of homology within which
gaps did not exceed 50 nucleotides. RepeatMasker was
run, to identify interspersed repeat sequences. The se-
quence between the ends of WBRCA1 and NBR2 (nu-
cleotides 59596–67624, referring to the AC060780 se-
quence) was analyzed by use of the NIX analysis
program (nucleotide identification of unknown se-
quences, U.K. Medical Research Council Human Ge-
nome Mapping Project), a Web-based package of
gene-analysis software (including GRAIL, GENSCAN,
Fgenes, Fex, Hexon, Genemark, Genefinder, BLAST,
Polyah, RepeatMasker, and TRNAscan).
Color Bar Coding the BRCA1 Region on Combed
DNA from Families F32 and F3514
DNA samples were extracted from lymphoblastoid
cell lines of BRCA1 carriers belonging to families F32
and F3514, as reported elsewhere (Michalet et al. 1997).
Combing relies on homogeneous stretching of DNA
molecules at a constant rate of 2 kb/mm (Bensimon et
al. 1994; Michalet et al. 1997). FISH was performed on
combed DNA, using six probes generated by random
labeling (as described by Gad et al. [2001a]) of a PAC
covering the whole BRCA1 region (PAC103O14 from
the chromosome 17 library of the Lawrence Livermore
National Laboratory [Brown et al. 1995]), a rearranged
cosmid covering the BRCA1 promoter region (cosmid
ICRFc105D06121 from the Ressourcen Zentrum Pri-
mary Database [Brown et al. 1996; Gad et al. 2001a]),
and four long-range (LR) PCR products (Expand Long
Template PCR System, Roche Diagnostics). Three PCR
products covered exons of the BRCA1 gene, and the
remaining one covered exons 2–4 of the NBR2 gene
(Gad et al. 2001a; primers used are available at the In-
stitut Curie Web site).
Full signals were observed under an epifluorescence
DMRB microscope (Leica) and were captured with
IPLab Spectrum-SU2 software (Vysis), using an NU 200
CCD camera (Photometrics). Image analyses were per-
formed with CartographiX software (X. Michalet, In-
stitut Pasteur, Paris), which permits the measurement of
fragments of full signals with respect to the constant
stretching rate of 2 kb/mm (Michalet et al. 1997; Gad
et al. 2001a).
Cloning of Breakpoints in Families F32 and F3514
PCRs were performed using the Expand Long Tem-
plate PCR System (Roche) according to the manufac-
turer’s recommendations. Among BRCA1 carriers in
families F32 and F3514, forward primer pintron2.2F
(ACC TAA AAT TCC TTC TGC TGG AC), which is
located within intron 2 of the pseudogene at the begin-
ning of block 11 (nucleotides 71699–71677), and re-
verse primer intron2.R2 (CCT TGG GCT AAC CAC
TCT ACC), which is located in intron 2 (nucleotides
33948–33968), gave products of ∼800 bp for F32 and
F3514 carriers’ DNA only, the normal fragment being
far too large (37.8 kb) to be amplified. These fragments
were then sequenced.
Screening for BRCA1 Rearrangements Involving
WBRCA1 in Families with Breast and Ovarian Cancer
An original set of ∼100 families, ascertained by H. T.
Lynch (Creighton University School of Medicine), were
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screened for mutations in the coding region and splice
sites of the BRCA1 and BRCA2 genes by use of het-
eroduplex analysis and the protein truncation test (Ma-
zoyer et al. 1996; Serova et al. 1996; Puget et al. 1997,
1999a, 1999b; Serova et al. 1997). Of the families that
remained negative for mutations, 13 were used in this
analysis. Families were selected according to the follow-
ing criteria: (1) at least 5 cases of breast cancer, of which
at least 4 were diagnosed at !60 years of age; (2) at least
4 cases of breast cancer, of which at least 2 were diag-
nosed at !45 years of age; (3) at least 1 case of ovarian
cancer diagnosed at any age and 3 cases of breast cancer
diagnosed at !60 years of age; or (4) at least 2 cases of
ovarian cancer diagnosed at any age and 1 case of breast
cancer diagnosed at !45 years of age or 2 cases of breast
cancer diagnosed at any age. Among these families, seven
are affected by breast cancer alone (one includes one
case of male breast cancer), whereas the remaining six
are families with breast and ovarian cancer (one includes
one case of male breast cancer).
Screening for rearrangements involving WBRCA1was
conducted with the following primer pairs: NBR1.1AF
(CCT GAGGCC TGA ATA TCA GC)/intron2.R4 (CTA
TCC TCT CAA CGA CAC CGA T) to amplify from
blocks 5–8; pintron2.7F (TCA AGG AAA TTT TCT
TTT GTG C)/intron2.R7 (TGT GGA GTT TCC CCC
ATT CT) to amplify blocks 10–14.
The expected size of the mutant product in the pres-
ence of a rearrangement is 2.4–2.9 kb for the first pair
and ∼7 kb for the second one. All screenedDNA samples
were subjected to a preliminary PCR with primers giving
rise to a 7.2-kb fragment, in order to check their quality.
A positive control—that is, carriers of BRCA1 from F32
and F3514, could only be used with primers pintron2.7F
and intron2.R7. More information about screening pro-
tocols, including the choice of primers, can be obtained
upon request from the corresponding author.
Results
Structure of the Region Upstream of the BRCA1 Gene
The complete genomic sequence of the humanBRCA1
gene (GenBank accession number L78833), which be-
gins 2,965 nucleotides upstream of exon 1A and there-
fore contains NBR2 exons 1A and 1B, was made avail-
able in 1996, 2 years after the BRCA1 cDNA was
cloned. Comparison of this sequence with available
NBR1 and WBRCA1 sequences (U72483 and U77841)
showed an overall similarity of 90.3%, scattered over
3,865 nucleotides. All attempts to amplify the region
between WBRCA1 and BRCA1 by long-range PCR with
a wide collection of primers have been unsuccessful, ei-
ther because this region was larger than the ∼30 kb
proposed or because it contained sequences difficult to
amplify or for both reasons. In the same way, we were
unable to amplify the region between WBRCA1 and
NBR2 or that between NBR2 exon 2 and BRCA1.
To obtain more information on the structure of this
region, we developed a restriction map of a 60-kb P1
clone (P1 1141 [Swensen et al. 1997]), from which we
deduced that most of BRCA1 intron 2 was likely to be
contained within the duplicated region (data not shown).
The deduction was later confirmed with the recently de-
posited sequence of BAC RP11-242D8 (GenBank ac-
cession number AC060780), which, at the present time,
consists of three contigs, among which a 152,199-nu-
cleotide piece comprises NBR1, WBRCA1, NBR2, and
39,879 nucleotides of BRCA1. Analysis of this sequence
revealed that BRCA1 exon 1A and WBRCA1 exon 1A
are 44,490 nucleotides apart. The duplicated segments
extend over 14,491 and 24,970 bp in theNBR2/BRCA1
and the NBR1/WBRCA1 regions, respectively, and are
fragmented in 14 blocks of homology (fig. 1 and table
1), ranging from 77 to 1,555 bp (total 11,429 bp). The
percentage of identity between gene and pseudogene
within blocks varies from 76.9 to 92.1 (table 1). Gaps
between blocks (61–7,457 bp) result from insertion or
deletion mostly of repetitive elements in BRCA1 or
WBRCA1 (fig. 1), with two exceptions: (1) a 3,794-bp
region containing repetitive elements, nonspecific se-
quences, and NBR1 exon 2 (between blocks 1 and 2)
and (2) a large P1 ribosomal protein pseudogene in the
WBRCA1 region (between blocks 5 and 6). The sequence
between WBRCA1 and NBR2 is 8,029 nucleotides and
was analyzed by the use of NIX, which incorporates a
number of independent gene-prediction tools. Although
a couple of genes were predicted (data not shown), no
known transcribed sequence was identified. Repeat-
Masker indicates that interspersed repeats account for
56.5% of this region.
Cloning of the Breakpoints of the Deletions in Families
F32 and F3514
In a previous study, we analyzed 78 DNA samples by
quantitative Southern blot hybridization, to assess the
proportion of rearrangements in the BRCA1 mutation
spectrum (Puget et al. 1999a). Densitometric analysis of
the blots showed, in two American families with breast
and ovarian cancer (F32 and F3514), deletions ofBRCA1
exons 1 and 2 but not of exon 3 or WBRCA1 exons 1
and 2 (Puget et al. 1999a). Allelotypingwith threeBRCA1
intragenic markers revealed that these two families do not
share a haplotype (Puget et al. 1999a). Further Southern
blot analysis with more probes showed that these dele-
tions totally encompass NBR2 (data not shown). To es-
timate the extent of the deleted regions in F32 and F3514,
the BRCA1 gene region was analyzed using the dynamic
molecular-combing technique in association with FISH
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Figure 1 Schematic representation of the duplicated regions showing the homology between NBR1 and NBR2, and between WBRCA1
and BRCA1. Blackened boxes represent exons, and shaded boxes represent blocks of homology, which were arbitrarily numbered. Repetitive
elements, i.e., Alu, L1/L2, LTR, SVA, and MIR sequences are also shown. Block 11, which contains the breakpoints of both deletions in families
F32 and F3514, is emphasized with an asterisk (*). The schema is drawn to scale.
(Bensimon et al. 1994; Michalet et al. 1997). Homoge-
neously stretched DNA molecules were visualized with a
four-color bar code, allowing the analysis of the whole
BRCA1 and upstream region (Gad et al. 2001a). As
shown in figure 2, two signal patterns were observed in
the F32 and F3514 DNA samples: the abnormal allele
showed a similar BRCA1 bar code in both cases, with
absence of hybridization of the NBR2 LR2–4 and of the
cosmid probe, which normally allows visualization of
both WBRCA1 and BRCA1 exons 1 and 2 because of
cross-hybridization, on one of its targets. Taken together
with the Southern blot results, these data suggested that
a deletion comprising the region between WBRCA1 and
BRCA1 had occurred in F32 and F3514 and had led to
the replacement of BRCA1 exons 1 and 2 by WBRCA1
exons 1 and 2.
In the same way that we were unable to amplify the
region between WBRCA1 and BRCA1 by long-range
PCR in control individuals, we were unable to amplify
the mutant allele with various combinations of forward
primers located in WBRCA1 exon 2 and reverse primers
located in BRCA1 exon 3 by long-range PCR, using a
wide range of conditions, although the expected frag-
ment was estimated to be !15 kb.
When sequence information concerning intron 2 of
the BRCA1 pseudogene became available, it gave us the
opportunity to design primers that specifically hybrid-
ized the pseudogene. Such forward primers were used
in conjunction with reverse primers specifically hybrid-
izing the BRCA1 gene. Primers pintron2.2F and in-
tron2.R2 gave rise to an ∼800-bp fragment when they
were used with DNA from members of families F32 and
F3514 who carried the deletion. No product was ob-
tained when these primers were used with DNA from
control individuals. Sequencing of this fragment revealed
that a 36,934-bp fragment, comprising BRCA1 exons 1
and 2 and the region located between WBRCA1 and
BRCA1, is deleted in both families. In F32, the break-
point junctions occurred in two regions of 237 bp
within block 11 with 100% similarity (nucleotides
34439–34675 in BRCA1 and nucleotides 71374–
71610 in WBRCA1, referring to the RP11-242D8 BAC
sequence). The breakpoint junctions in F3514 occurred
in 23-bp regions of perfect homology, located 77 bp
apart (nucleotides 34,339–34,361 in BRCA1 and nu-
cleotides 71,274–71,296 in WBRCA1). These regions do
not contain any repetitive element.
Because of the deletions, carriers in families F32 and
F3514 harbor a chimeric gene that consists of WBRCA1
exons 1A, 1B, and 2 fused to BRCA1 exons 3–24 (fig.
3). As a consequence, the BRCA1 promoter is absent
from this mutant allele. It is not known yet whether the
BRCA1 pseudogene is transcribed, and therefore we
do not know whether the mutant gene might be ex-
pressed. Nevertheless, all attempts to identify a mu-
tant transcript were unsuccessful (data not shown). In
any case, and although both exons 2 are highly similar,
the methionine codon used as the BRCA1 translation
initiation codon is lost in the chimeric gene, because it
is changed to an isoleucine codon in WBRCA1. Missense
mutations changing this methionine codon to a valine
or an isoleucine codon have been reported in five families
with breast and ovarian cancer (Breast Cancer Infor-
mation Core). It implies that even if other methionine
codons can be used for translation initiation; as has been
suggested elsewhere (Liu et al. 2000), the resulting
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Table 1











NBR1 or WBRCA1 NBR2 or BRCA1 NBR1 or WBRCA1 NBR2 or BRCA1
1 92098–92594 45329–45863 542 83.9 3,794 0
2 87618–88303 44646–45328 689 91.0 306 0
3 86955–87311 44276–44645 388 81.2 1 316
4 86005–86953 43004–43958 974 89.6 0 1,853
5 84706–86004 39874–41150 1,321 86.4 343 0
6 83959–84362 39472–39873 405 87.7 61 0
7 83161–83897 38695–39471 781 88.9 315 0
8 82187–82845 38031–38684 667 92.1 7,457 0
9 74455–74729 37761–38030 281 76.9 796 443
10 72200–73658 35887–37317 1,473 87.4 4 623
11 70684–72195 33720–35263 1,555 90.3 194 0
12 69048–70489 32241–33719 1,482 91.5 62 0
13 68196–68985 31450–32240 794 91.2 494 0
14 67625–67701 31373–31449 77 87.0 … …
Total 11,429
BRCA1 isoform cannot substitute for the tumor-sup-
pressor function of the wild-type protein in breast and
ovarian tissues.
Screening for Rearrangements Involving the WBRCA1
in Families with Breast and Ovarian Cancer
The identification of two different recombination
events involving homologous regions located respectively
in the BRCA1 gene and WBRCA1 leads to the possibility
that these regions represent a strong hot spot for recom-
bination.We therefore screened additional candidate fam-
ilies for the presence of such deletions, with two different
combinations of forward primers located in NBR1 or
WBRCA1 and reverse primers located in BRCA1. The 13
tested families with breast and ovarian cancerwere chosen
on the basis of strict criteria and were negative in a mu-
tation screening analysis of the BRCA1 and BRCA2 cod-
ing sequence and splice sites. The BRCA1 promoter lies
between exons 1A of NBR2 and BRCA1. Therefore, re-
arrangements involving blocks 1–5 would disrupt the
NBR1 and the NBR2 genes but would not disrupt any
part of the BRCA1 gene, including its promoter. We
thus focused our analysis on screening for rearrange-
ments within blocks 6–14. Because of difficulties, as
mentioned above, in amplifying the region between
NBR1 and BRCA1, we split the screened interval into
two segments: blocks 5–8 and blocks 10–14 (see fig. 1).
No other large deletions resulting from recombination
between BRCA1 and its pseudogene were observed.
Discussion
We show here that the first exons of the BRCA1 gene
were replaced, in carriers from two families with breast
and ovarian cancer, by those of the BRCA1 pseudogene,
WBRCA1 (fig. 3). Among the 14 blocks of homology
identified between the NBR1/WBRCA1 and the NBR2/
BRCA1 regions, the breakpoint junctions of the 37-kb
deletions identified in families F32 and F3514 were both
found to be located in block 11 (fig. 1), at close but
distinct sites within segments of 624 bp that are 98%
identical. These segments contain the longest stretches
of complete sequence identity found among any of the
14 blocks: 237 and 188 bp, compared with !115 bp.
The mutant alleles harbor a chimeric gene that consists
of WBRCA1 exons 1A, 1B, and 2 fused to BRCA1 exons
3–24 (fig. 3). This chimeric gene lacks the BRCA1 pro-
moter and the BRCA1 translation initiation codon. The
concomitant absence of the NBR2 gene in the mutant
alleles does not appear to lead to a contiguous-gene-
deletion syndrome, because carriers from families F32
and F3514 do not show any remarkable phenotypic trait
apart from being predisposed to breast and ovarian can-
cers (10 cases of breast cancer and 2 cases of ovarian
cancer in family F32; 2 cases of breast cancer, 1 case of
ovarian cancer, and 1 case of bilateral breast cancer and
ovarian cancer in family F3514). It should be noted that
nothing is known, as yet, about the potential protein
encoded by NBR2.
The screening of 13 additional highly selected fam-
ilies with breast and ovarian cancer, negative after in-
tensive searches for BRCA1 and BRCA2 mutations,
failed to identify any more large deletions resulting
from homologous recombination between BRCA1 and
WBRCA1. More such families should be tested with
the primers we describe, to determine the frequency of
these alterations in the BRCA1 mutation spectrum.
Notably, two families with breast and ovarian cancer
that were reported in the literature to present an ab-
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Figure 2 BRCA1 color bar code of DNA samples from families F32 and F3514. Two allele populations could be visualized under a
microscope when combed DNA samples were hybridized with fluorescent probes generated from PAC 103O14 (green) and cosmid D06121
(red) and from long-range PCR products NBR2 LR2-4 (blue), BRCA1 LR9-12 (blue), BRCA1 LR16-19 (deep pink), and BRCA1 LR24-3′
(blue). The sizes of the probes are indicated. The expected normal bar code for the wild-type allele was WBRCA1-NBR2-BRCA1 exons 1–2,
9–12, 16–19, and 24, as shown in A and C, for F32 and F3514, respectively. This pattern was found in 18 full signals (50%) for F32 and 26
full signals (58%) for F3514. An abnormal, shorter signal, without the 5′ part of the normal pattern, as shown in B and D, for F32 and F3514,
respectively, was also found in 18 full signals (50%) for F32 and 19 full signals (42%) for F3514, corresponding to the mutant alleles with
the deletion.
normal pattern in Southern blot experiments, with
probes covering BRCA1 exons 1 and 2 (Unger et al.
2000), might carry a recombination event involving
WBRCA1.
Duplication of genes, gene segments, and repeat-gene
clusters generated by the evolution of the mammalian
genome provides substrates for homologous recombi-
nation that results in DNA rearrangements. When re-
arrangements alter the genome by causing complete loss
or gain of a gene(s) sensitive to a dosage effect or by
disrupting the structural integrity of a gene, they are
responsible for many diseases called “genomic dis-
orders.” These include notably a- and b-thalassemia,
hemophilia A, growth hormone deficiency, Charcot-
Marie-Tooth disease type 1A (CMT1A), hereditary
neuropathy with liability to pressure palsies (HNPP)
and Smith-Magenis syndrome (for review, see Lupski
1998). Several common features associated with the
mechanisms that lead to DNA rearrangements were ap-
parent when analyzing such diseases: (1) long regions
of high similarity appear to be required for recombi-
nation, and (2) the greater the distance between repeats,
the greater the repeat length required for efficient re-
combination. This is exemplified by unequal crossing-
over events causing a-thalassemia, which involve re-
peated segments of ∼4 kb located 3.7 or 4.2 kb apart
within the a-globin locus; causing hemophilia A, which
involve 98% identical repeats of 9.6 kb located ∼500
kb apart within the factor VIII gene locus; and causing
CMT1A and HNPP, which involve repeats (CMT1A-
REPs) of 24 kb 198% identical located 1,500 kb apart.
DNA sequence analysis of the junctions of the recom-
binations responsible for genomic disorders showed
those crossing-over events took place in shorter regions
within the repeats where the sequence identity is the
strongest. Alternatively, specific elements that may stim-
ulate recombination, such as MITE (x- andmariner-like
transposable element) and a x-like sequence, were found
in or close to the 1.4-kb CMT1-REP hot spot (Reiter
et al. 1996) and the 2-kb NF1-REP hot spot (Lopez-
Correa et al. 2001), respectively.
In the case of the BRCA1 locus, the duplicated region
is 110 kb and is located !50 kb upstream of BRCA1,
which makes homologous recombination events likely to
occur frequently. However, the requirement of an overall
high similarity between the repeated segments is not met,
because of numerous interruptions generated by inser-
tions and/or deletions of repetitive sequences (see fig. 3).
The fact that the duplicated copy and the original one
diverged from one another to such an extent might be
related to the unusually high content of repetitive ele-
ments in the BRCA1 gene (Smith et al. 1996). In the case
of the disorders mentioned above, genome rearrange-
ments represent a high proportion of mutations. Con-
trary to this, it seems clear from the data obtained in our
panel of ∼100 families with breast and ovarian cancer
that rearrangements between BRCA1 and WBRCA1 are
heavily outnumbered by point mutations, small inser-
tions, small deletions, and splice-site mutations. This
might be explained by the overall low similarity of the
repeats (as mentioned above), associated with the large
size of theBRCA1 coding sequence, which providesmore
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Figure 3 Representation of the 37-kb deletion in F32 and F3514. Drawn-to-scale schema of the normal and mutant alleles at the NBR1
and BRCA1 loci, showing the location of the 36,934-bp deletion. The size of the NBR1, WBRCA1, NBR2, and BRCA1 genes are given in
parentheses in the normal allele schema.
opportunities for mutations during replication. Never-
theless, it is reasonable to expect more families with
breast and/or ovarian cancer worldwide to carry large
deletions, like the ones described here. Therefore, screen-
ing protocols should include PCR assays, such as those
described in the present article, to detect this new type
of BRCA1 rearrangement in families with breast and
ovarian cancer that have nomutation inBRCA1/2 coding
sequences and splice sites.
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